Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The neuromuscular junction lies beyond the protection of the blood-brain barrier and is particularly vulnerable to antibody-mediated attack. In myasthenia gravis, the expression of acetylcholine receptors (AChRs) in the thymus is under the control of the autoimmune regulator protein (AIRE), and polymorphisms in the AChR correlate with early onset of disease. In some 'AChR seronegative' patients, thymic abnormalities associated with complement-activating antibodies binding only clustered AChRs have been demonstrated, and in others anti-muscle-specific kinase (MuSK) antibodies that show pathogenic effects in vivo. In Guillain-Barré syndrome, newly described antibodies bind to complex gangliosides. General immunosuppression is still the main treatment, but novel treatments that reduce complement-mediated damage or inhibit the binding of pathogenic antibodies are beginning to look promising.

Original publication

DOI

10.1016/j.coph.2009.04.005

Type

Journal article

Journal

Curr Opin Pharmacol

Publication Date

06/2009

Volume

9

Pages

336 - 340

Keywords

Animals, Disease Models, Animal, Guillain-Barre Syndrome, Humans, Immunosuppressive Agents, Immunotherapy, Isaacs Syndrome, Lambert-Eaton Myasthenic Syndrome, Myasthenia Gravis, Neuromuscular Junction Diseases